找回密碼
 To register

QQ登錄

只需一步，快速開(kāi)始

掃一掃，訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T

[復(fù)制鏈接]
查看: 18223|回復(fù): 54
樓主
發(fā)表于 2025-3-21 16:11:48 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
期刊全稱Biosimilars for Cancer Treatment
期刊簡(jiǎn)稱A Promising Approach
影響因子2023Shvetank Bhatt,Harish Dureja,Kamal Dua
視頻videohttp://file.papertrans.cn/193/192718/192718.mp4
發(fā)行地址Covers the recent clinical trials of biosimilars for cancer treatment.Provides information about the analysis of regulatory complexities in cancer care.Explores the role of biosimilars in improving th
圖書(shū)封面Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T
影響因子.The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers...It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments...This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment..
Pindex Book 2024
The information of publication is updating

書(shū)目名稱Biosimilars for Cancer Treatment影響因子(影響力)




書(shū)目名稱Biosimilars for Cancer Treatment影響因子(影響力)學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment被引頻次




書(shū)目名稱Biosimilars for Cancer Treatment被引頻次學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment年度引用




書(shū)目名稱Biosimilars for Cancer Treatment年度引用學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment讀者反饋




書(shū)目名稱Biosimilars for Cancer Treatment讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics
 

0票 0%

Better Implies Difficulty
 

0票 0%

Good and Satisfactory
 

0票 0%

Adverse Performance
 

0票 0%

Disdainful Garbage
您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:48:20 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:51:31 | 只看該作者
地板
發(fā)表于 2025-3-22 07:58:13 | 只看該作者
5#
發(fā)表于 2025-3-22 10:20:44 | 只看該作者
6#
發(fā)表于 2025-3-22 15:49:15 | 只看該作者
7#
發(fā)表于 2025-3-22 19:01:48 | 只看該作者
8#
發(fā)表于 2025-3-23 00:21:12 | 只看該作者
U. M. Lütolf,P. Huguenin,C. Glanzmann for use in both the disease itself and as supportive drugs for cancer patients. The reduction in the treatment cost using trastuzumab biosimilars is approximately 20–30% lower in comparison to the costs using the reference product. The supportive drugs include haematopoietic growth factors like ery
9#
發(fā)表于 2025-3-23 01:35:18 | 只看該作者
10#
發(fā)表于 2025-3-23 09:02:06 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 16:20
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
库尔勒市| 当阳市| 南部县| 民权县| 蒙山县| 高阳县| 普陀区| 扎鲁特旗| 眉山市| 武宁县| 萝北县| 左云县| 雅安市| 山西省| 蓬安县| 塘沽区| 舒兰市| 呼图壁县| 获嘉县| 安新县| 缙云县| 永川市| 南陵县| 武威市| 无棣县| 鲜城| 玉山县| 临洮县| 南康市| 湄潭县| 金平| 泽州县| 扶沟县| 长垣县| 广州市| 砚山县| 徐汇区| 胶州市| 公安县| 舞钢市| 新余市|